ICON Reports second quarter 2013 Revenue of $334 million, up 21% year on year, non-GAAP EPS of 43c and raises FY 2013 Guidance.

Highlights – Second Quarter Fiscal 2013.

  • Quarter 2 net revenue increased 21% year on year to $334 million.
  • Income from operations, excluding restructuring charges of $4.6 million, was $30.9 million or 9.3% of revenue.
  • Earnings per share excluding restructuring charges, was 43 cents.
  • Gross Business wins were $496 million, representing a gross book to bill of 1.48. Net business wins were $364 million, representing a net book to bill of 1.1.
  • FY 2013 Guidance updated: Revenue in the range of $1,300 million - $1,320 million and EPS in the range of $1.54 - $1.64.

DUBLIN--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2013.

Net revenues grew 21% year on year to $334.2 million from $277.0 million in Q2 2012.

Income from operations, excluding restructuring charges of $4.6 million, was $30.9 million or 9.3% of revenue, compared to $16.6 million or 6.0% for the same quarter last year.

Net income, excluding restructuring charges, was $26.5 million or 43 cents per share on a diluted basis, compared with $12.9 million or 21 cents per share last year.

Revenue in the first half of 2013 increased 23% to $651 million from $529 million in 2012.

Income from operations in the first half of 2013, excluding restructuring charges, was $58.3 million or 9.0% of revenue, compared with $28.4m or 5.4% of revenue in the previous year.

Net income, in the first half of 2013, excluding restructuring charges, was $48.7 million or 79 cents per share on a diluted basis, compared with $21.9 million or 36 cents per diluted share last year.

Guidance for the full year 2013 has been updated with revenue expected to be in the range of $1.3 billion - $1.32 billion and EPS guidance in the range of $1.54 - $1.64.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 33 days at June 30, 2013, compared with 40 days at the end of December 2012.

For the quarter ended June 30, 2013, cash generated from operating activities was $10.8 million after expenditure of $26 million on prior period acquisition earn outs and capital expenditure of $7.8 million. The company's net cash amounted to $184 million at June 30, 2013, compared to net cash of $190 million at December 31, 2012.

During the quarter the company recorded a charge of $4.6 million in relation to various restructuring costs. US GAAP income from operations after these items amounted to $26 million or 7.9% of revenue. US GAAP net income for the quarter was $22 million or 36 cents per share.

CEO Ciaran Murray commented, "I am happy that Q2 was another strong quarter for ICON. We reported revenue growth of 21% year on year and operating margins of 9.3%. We have continued to book satisfactory levels of new business and our trailing twelve month book to bill now stands at 1.3. Consequently we are raising our revenue guidance to the range of $1.3-$1.32 billion and our EPS guidance to the range of $1.54-$1.64 for the financial year 2013."

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold its second quarter conference call today, July 25, 2013 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 78 locations in 37 countries and has approximately 10,170 employees. Further information is available at www.iconplc.com.

Source: ICON plc

Contact: Investor Relations 1-888-381-7923 or

Brendan Brennan Chief Financial Officer + 353 –1-291-2000 or

Simon Holmes EVP Investor Relations and Corporate Development + 353 –1-291-2000

All at ICON.

ICON/ICLR-F

 

ICON plc

Consolidated Income Statements (Unaudited)

(Before restructuring and other items)

Three and Six Months ended June 30, 2013 and June 30, 2012

(Dollars, in thousands, except share and per share data)

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

  June 30,   June 30,   June 30,  

 

 

2013

  2012   2013   2012  
                   
Gross Revenue   469,626   379,620   888,685   722,675  
                   
Reimbursable expenses   135,407   102,613   237,677   193,335  
                   
Net Revenue   334,219   277,007   651,008   529,340  
                   
Costs and expenses                  
Direct costs   214,231   180,127   416,592   342,411  
Selling, general and administrative   77,548   69,410   153,112   136,925  
Depreciation and amortization   11,520   10,830   22,976   21,632  
                   
Total costs and expenses   303,299   260,367   592,680   500,968  
                   
Income from operations   30,920   16,640   58,328   28,372  
                   
Net interest expense   (100)   (231)   (285)   (266)  
                   
Income before provision for income taxes   30,820   16,409   58,043   28,106  
                   
Provision for income taxes   4,315   3,514   9,336   6,240  
                   
                   
Net income   26,505   12,895   48,707   21,866  
                   
Net income per ordinary share                  
Basic   $0.44   $0.21   $0.80   $0.36  
                   
Diluted   $0.43   $0.21   $0.79   $0.36  
                   
Weighted average number of ordinary shares                  
Basic   60,724,296   59,978,509   60,555,945   60,032,306  
                   
Diluted   61,898,903   60,630,891   61,607,757   60,607,635  
                   

 

ICON plc

Consolidated Income Statements (Unaudited)

(US GAAP)

Three and Six Months ended June 30, 2013 and June 30, 2012

(Dollars, in thousands, except share and per share data)

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

  June 30,   June 30,   June 30,  

 

 

2013

  2012   2013   2012  
                   
Gross Revenue   469,626   379,620   888,685   722,675  
                   
Reimbursable expenses   135,407   102,613   237,677   193,335  
                   
Net Revenue   334,219   277,007   651,008   529,340  
                   
Costs and expenses                  
Direct costs   214,231   180,127   416,592   342,411  
Selling, general and administrative   77,548   69,410   153,112   136,925  
Depreciation and amortization   11,520   10,830   22,976   21,632  
Restructuring and other items   4,621   5,636   9,033   5,636  
                   
Total costs and expenses   307,920   266,003   601,713   506,604  
                   
Income from operations   26,299   11,004   49,295   22,736  
                   
Net interest expense   (100)   (231)   (285)   (266)  
                   
Income before provision for income taxes   26,199   10,773   49,010   22,470  
                   
Provision for income taxes   3,720   2,809   7,486   5,535  
                   
                   
Net income   22,479   7,964   41,524   16,935  
                   
Net income per ordinary share                  
Basic   $0.37   $0.13   $0.69   $0.28  
                   
Diluted   $0.36   $0.13   $0.67   $0.28  
                   
Weighted average number of ordinary shares                  
Basic   60,724,296   59,978,509   60,555,945   60,032,306  
                   
Diluted   61,898,903   60,630,891   61,607,757   60,607,635  
                   

 

ICON plc

Summary Balance Sheet Data

June 30, 2013 and December 31, 2012

(Dollars, in thousands)

    June 30,   December 31,  
    2013   2012  
    (Unaudited)   (Audited)  
           
           
Net cash   183,903   190,230  
           
Accounts receivable   305,805   285,419  
Unbilled revenue   140,145   112,483  
Payments on account   (272,019)   (219,467)  
Total   173,931   178,435  
           
Working Capital   253,507   250,326  
           
Total Assets   1,293,122   1,202,108  
           
Shareholder's Equity   801,708   754,575  

 

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.